Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

CBIZ, Inc. (NYSE: CBZ), a leading national professional services advisor, announced the release of its 2025 State of ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...

Despite its popularity, Ozempic often leads to temporary weight loss, carries serious side effects, and most users regain ...

As weight loss medications like Ozempic continue to gain popular, experts and patients are noticing varying effects of the ...

If you’ve been on TikTok or any other social media — or any kind of media, for that matter — you’ve probably come across ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

A former head of the US Food and Drug Administration cut his body fat in half using GLP-1 drugs. In his book, he compares the ...